BiotechTube
Home/Senti Biosciences/Jay Cross
JC

Jay Cross

Chief Financial Officer

Senti Biosciences

Therapeutic Areas

OncologyHematology

Senti Biosciences Pipeline

DrugIndicationPhase
SENTI-202Acute Myeloid Leukemia (AML)Phase 1
SENTI-401Colorectal Cancer (CRC)Preclinical

Leadership Team at Senti Biosciences

TL
Timothy Lu
Co-Founder and Chief Executive Officer
KR
Kanya Rajangam
President, Head of Research & Development and Chief Medical Officer
View full Senti Biosciences profile